Production of interstitial pneumonia in mice and rats by administration of component preparations of mycoplasma, lectins and other non-viable compounds, and screening for the protective immunogen components of Mycoplsma pulmonis

利用从肺支原体中分离的组分，我们制备了小鼠和大鼠中支原体诱导的间质性肺炎的各种肺病变特征，以阐明这种形式的肺炎的特征，作为研究支原体感染的化疗和筛选小鼠中支原体诱导的肺炎的保护性免疫原的基础。通过给予非活性成分产生间质性肺炎：通过鼻内给予对肺具有交叉反应抗原性的复合肾原苷和具有促分裂活性和从支原体培养滤液中分离的纯化抗原的抗原性的ConA，我们能够几乎完全重现间质性肺炎，其中从支原体感染的早期至最大期，在肺中可见淋巴细胞对血管周围和肺泡壁的浸润。然而，肺内和支气管周围的炎症只能通过给药的肺支原体的纯化膜。据认为，感染引起的宿主全身免疫变化是这些症状发展为慢性间质性肺炎的必要条件。单用抗生素对这种肺炎没有足够的治疗效果。相比之下，免疫抑制剂（泼尼松龙，环孢菌素A）和免疫调节剂（白细胞介素-2）与抗生素（米诺霉素）的联合给药导致治疗效果，使用这些药物的研究仍在继续探索其作用机制，以确定有效的治疗形式。在本研究中使用的实验小鼠为基础的感染系统的主动和被动免疫接种肺支原体诱导的小鼠肺炎提供了经验证据的存在的抗原成分的生物体，提供显着更大的保护小鼠对肺支原体。

Using components isolated from Mycoplasma pulmonis, we prepared various lung lesions characteristic of mycoplasma-induced interstitial pneumonia in the mouse and rat to clarify the character of this form of pneumonia as a basis for the investigation of chemotherapy of mycoplasma infections and screening for a protective immunogen to M.pulmonis-induced pneumonia in mice. Production of iterstitial pneumonia by administration of non-viable components:We were able to almost completely reproduce interstitial pneumonia in which perivascular and alveolar wall infiltration by lymphocytes can be seen in the lung from the early to maximum phase of mycoplasma infection by intranasal administration of a compound nephritogenoside, which has cross-reactive antigenicity towards the lung, and ConA, which has mitogen activity and the antigenicity of purified antigen isolated from mycoplasma culture filtrate. However, intratracheal and peribroncheal inflammations could only be induced by administration of the purified membrane of M.pulmonis. It is believed that infection-induced systemic immunological change of the host is requisite for these symptoms to develop into chronic interstitial pneumonia. Administration of antibiotics alone does not have an adequate therapeutic effect on this pneumonia. By contrast, combined administration of the immunosuppressants (prednisolone, cyclosporin A) and the immunomodulator (interleukin-2) with the antibiotic (minomycine) leads to therapeutic efficacy and studies using these drugs are still continuing to explore the mechanisms on which they act to determine an efficacious from of therapy. The experimental mouse-based infection system used in the present study for active and passive immunization of M.pulmonis-induced pneumonia in mice provided empirical evidence of the existence of antigenic components of organisms that offer significantly greater protection of mice against M.pulmonis.